mobocertinib succinate - Profile

What are the generic drug sources for mobocertinib succinate and what is the scope of patent protection?

Mobocertinib succinate is the generic ingredient in one branded drug marketed by Takeda Pharms Usa and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Mobocertinib succinate has sixty-five patent family members in forty countries.

Summary for mobocertinib succinate

International Patents:	65
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for mobocertinib succinate

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for mobocertinib succinate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	EXKIVITY	mobocertinib succinate	CAPSULE;ORAL	215310-001	Sep 15, 2021		DISCN	Yes	No			Y	Y
Takeda Pharms Usa	EXKIVITY	mobocertinib succinate	CAPSULE;ORAL	215310-001	Sep 15, 2021		DISCN	Yes	No			Y	Y
Takeda Pharms Usa	EXKIVITY	mobocertinib succinate	CAPSULE;ORAL	215310-001	Sep 15, 2021		DISCN	Yes	No
Takeda Pharms Usa	EXKIVITY	mobocertinib succinate	CAPSULE;ORAL	215310-001	Sep 15, 2021		DISCN	Yes	No

International Patents for mobocertinib succinate

Country	Patent Number	Title	Estimated Expiration
Georgia, Republic of	AP202014706
Japan	2021181486
Turkey	201903322
Japan	2021181486	キナーゼ阻害のためのヘテロアリール化合物 (HETEROARYL COMPOSITION FOR KINASE INHIBITION)
Tunisia	2016000560	HETEROARYL COMPOUNDS FOR KINASE INHIBITION
European Patent Office	3409669	COMPOSÉS HÉTÉROARYLES POUR INHIBITION DE KINASE (HETEROARYL COMPOUNDS FOR KINASE INHIBITION)

Supplementary Protection Certificates for mobocertinib succinate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3157916	SPC/GB22/041	United Kingdom		PRODUCT NAME: MOBOCERTINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, FOR EXAMPLE, MOBOCERTINIB SUCCINATE; REGISTERED: UK PLGB 16189/0124-0001 20220317
3157916	C03157916/01	Switzerland		PRODUCT NAME: MOBOCERTINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68147 01.06.2022

Investment Scenario and Fundamentals Analysis for Mobocertinib Succinate

Last updated: March 2, 2026

What is the current market status of Mobocertinib Succinate?

Mobocertinib succinate (EXKIVITY) is an oral tyrosine kinase inhibitor developed for targeting epidermal growth factor receptor (EGFR) exon 20 mutations. It received FDA approval in September 2021 for previously treated non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. As of 2023, it remains in early commercialization stages, primarily supplied via North American distribution channels.

How does the drug’s pipeline impact its investment prospects?

Mobocertinib’s clinical development pipeline is limited compared to broader EGFR inhibitor portfolios. Phase 2 trial data demonstrated response rates of approximately 28% in targeted NSCLC populations, with a manageable safety profile, providing a foundation for potential label expansion. However, no significant indications beyond NSCLC are confirmed, constraining long-term pipeline value.

What are the key financial and commercial fundamentals?

Parameter	Details
Launch year	2021
Major markets	North America, limited expansion in Europe as of 2023
Estimated annual sales (2023)	$200 million to $300 million (initial estimates)
Pricing	Approx. $15,000 per month (varies by payer and region)
Market penetration	Early-stage, primarily treatment of EGFR exon 20 NSCLC
Competition	Amgen's Amgevita, Sachin's Amgevita, other EGFR inhibitors
Patent status	Patent protection through at least 2030
Regulatory status	Approved by FDA; EMA approval pending in Europe

How does the competitive landscape influence investment outlook?

Mobocertinib faces competition from emerging therapies targeting EGFR exon 20 mutations, including:

• Amgen's AMG 510 (sotorasib) and AMG 701 (adagrasib), targeting KRAS G12C but with potential crossover applications.
• Eisai's drug candidates with similar mechanisms.
• Chemotherapy, immunotherapy, and newer targeted therapies.

Market share gains depend on drug efficacy, safety, and approval of competitory agents. Mobocertinib's differentiated profile depends on response rate, side effects, and convenience.

What are the regulatory and commercialization risks?

Regulatory approvals are stable in North America but face limitations elsewhere. Key risks include:

• Approval delays or rejections outside the US.
• Patent cliff risks beyond 2030.
• Pricing negotiations pressure and reimbursement hurdles.
• Competitive advances leading to obsolescence or selection bias.

What is the financial outlook considering R&D, approval, and commercialization?

Aspect	Details
R&D investment	About $50 million annually for ongoing trials and monitoring
Margin potential	Estimated Gross Margin: 65%; Net Margin: 20-30% post-launch
Cost of goods sold (COGS)	Approx. 20% of sales
Break-even point	Estimated within 3-4 years post-launch

Investors should consider the early-stage nature of commercialization and investment costs. The potential for early sales growth exists, but scaling depends on market acceptance and competitive dynamics.

How does patent expiry and lifecycle management affect valuation?

Existing patents extend into the early 2030s, providing market exclusivity. Lifecycle extension strategies include:

• Label expansion to additional NSCLC subpopulations,
• Combination therapies,
• Explorations in other solid tumors with EGFR mutations.

Patent expiry risks could erode market share if competitors introduce superior or more effective treatments.

Key Takeaways

• Mobocertinib succinate is a targeted NSCLC therapy with FDA approval since 2021.
• The drug's market is nascent, with projected first-year sales in the low hundreds of millions.
• Competition from other EGFR inhibitors and emerging therapies presents significant market risks.
• Commercial success depends on effective market penetration, payer negotiations, and regulatory expansion.
• Patent protection extends into the early 2030s; lifecycle management is vital for maintaining value.

FAQs

1. What are the primary drivers of Mobocertinib's revenue growth?
Market penetration in EGFR exon 20 NSCLC, expansion into other indications, and continued acceptance by oncologists.

2. What regulatory hurdles could impact future sales?
Delayed or denied approvals outside North America and regulatory restrictions due to safety or efficacy concerns.

3. How does Mobocertinib compare to other EGFR inhibitors?
It is selective for exon 20 mutations, offering potential differentiation. However, other drugs like osimertinib have broader indications and established safety profiles.

4. What are the potential risks associated with patent expiry?
Loss of exclusivity could lead to generic competition, pressure on prices, and reduced margins.

5. How significant is the pipeline for long-term valuation?
Limited beyond NSCLC, so pipeline diversification is necessary for sustained growth; current data do not suggest imminent expansion.

References

[1] Food and Drug Administration. (2021). FDA approves Mobocertinib for NSCLC with EGFR exon 20 insertion mutations.
[2] Pharma Intelligence. (2023). Market analysis report on EGFR inhibitors.
[3] IQVIA. (2023). Global Oncology Market Trends.
[4] European Medicines Agency. (2023). Pending approvals for Mobocertinib.